EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review

Hitomi Sakai iD, Junji Tsurutani

Translational Breast Cancer Research · 2026-07 · 7 · 28-28

DOI: 10.21037/tbcr-25-29 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Translational Breast Cancer Research, 2026-07. Verfasst von Hitomi Sakai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Cancer Translational Research Institute, Showa Medical University, Tokyo, Japan. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Human epidermal growth factor receptor 2 (HER2)breast cancerefficacytoxicity

Autor:innen und Institutionen

  • Advanced Cancer Translational Research Institute, Showa Medical University, Tokyo, Japan.

ORCID-Profile: Hitomi Sakai

Zitieren

APA

Sakai, H., & Tsurutani, J. (2026). Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review. Translational Breast Cancer Research, 7, 28-28. https://doi.org/10.21037/tbcr-25-29

Vancouver

Sakai H, Tsurutani J. Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review. Translational Breast Cancer Research. 2026;7:28-28. doi:10.21037/tbcr-25-29

BibTeX
@article{Sakai2026,
  author = {Sakai, Hitomi and Tsurutani, Junji},
  title = {Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review},
  journal = {Translational Breast Cancer Research},
  year = {2026},
  volume = {7},
  pages = {28--28},
  doi = {10.21037/tbcr-25-29}
}
Kostenlos starten →